Position:
Clinical Assistant Professor
Division:
Medical Oncology
Research Interests:
  1. Primary and secondary CNS lymphomas
  2. Mantle cell lymphoma
  3. Transformed indolent lymphoma
  4. Diffuse large B-cell lymphoma

 

Recent Publications:
  1. Scott DW, Abrisqueta P, Wright G, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Braziel RM, Chan WC, Weisenburger D, Cook J, Greiner T, Fu K, Ott G, Delabie J, Smeland E, Holte H, Jaffe E, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt L, Campo E, Rimsza L. A new molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies.  Journal of Clinical Oncology.  Epub ahead of print March 2017.
  2. Moffitt A, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, The CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh N, Villa D, Gascoyne RD, Said J, Czader M, Chadburn M, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi E. Enteropathy associated T-cell lymphoma subtypes are characterized by loss of function of SETD2.  Journal of Experimental Medicine 2017; 214(5).
  3. El-Galaly TC, Villa D, Michalesen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Johnsen HE, Seymour JF, Connors JM, Brown PdN, Bogsted M, Cheah CY. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with DLBCL: An international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer 2017; 75: 195-203.
  4. Limvorapitak W, Villa D. Acquired blue sclerae in POEMS Syndrome. British Journal of Haematology.  Epub ahead of print 17 April 2017.
  5. Villa D. Novel antivirals for HCV-associated lymphomas. Blood 2016; 128: 2482-2483.
  6. El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel G, Savage KJ, Sehn LH, Barrington S, Hansen J, Poulsen M, Smith D, Rady K, Mylam KJ, Larsen T, Holmberg S, Juul M, Cordua S, Clausen M, Jensen K, Bogsted M, Johnsen H, Seymour J, Connors JM, Brown P, Villa D. Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. British Journal of Haematology 2016; 175(5): 876-883.
  7. Kansara R, Connors JM, Savage KJ, Gerrie AS, Scott DW, Slack GW, Gascoyne RD, Sehn LH, Villa D. Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. Haematologica 2016; 101(10): 411-14.
  8. Alzahrani M, El-Galaly TC, Hutchings M, Hansen JW, Loft A, Johnsen HE, Iyer V, Wilson D, Sehn LH, Savage KJ, Connors JM, Gascoyne RD, Clasen-Linde E, Brown P, Villa D. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: A Danish-Canadian study. Annals of Oncology 2016; 27(6): 1095-9.
  9. Dunbar M, Dilli E, Slack GW, Villa D. Chronic lymphocytic leukemia presenting with concurrent isolated CNS parenchymal and leptomeningeal large B-cell lymphoma.  Annals of Hematology and Oncology 2016; 3(6): 1-5.
  10. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD. The impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016; 127(18): 2182-8.
  11. Loree JM, Cai E, Sheffield BS, Dutz JP, Villa D, Shepherd LE, Connors JM, Sehn LH, Savage KJ. Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leukemia & Lymphoma.  First published online August 2016.
  12. Hapgood G, Sehn L, Scott D, Villa D, Gerrie A, Klasa R, Gascoyne R, Slack G, Aquino-Parsons C, Morris J, Pickles T, Connors J, Savage K. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20 year British Columbia Cancer Agency experience. British Journal of Haematology.  Epub ahead of print Oct 2016.
  13. Kridel R, Telio D, Villa D, Sehn L, Gerria A, Shenkier T, Klasa R, Slack G, Tan K, Gascoyne R, Connors J, Savage K. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. British Journal of Haematology.  Epub ahead of print Oct 2016.
  14. Cheah CY, Brockelmann PJ, Chihara D, Moskowitz A, Engert A, Jerkeman M, El-Galaly TC, Auguston B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: an international multicenter collaboration. American Journal of Hematology 2016; 91(9): 894-9.
  15. Kansara R, Villa D, Gerrie AS, Klasa R, Shenkier T, Scott DW, Slack GW, Gascoyne RD, Connors JM, Sehn LH, Savage KJ. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. British Journal of Haematology. Epub ahead of print July 2016.
  16. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. Journal of Clinical Oncology 2016; 34(26): 3150-6.
  17. Hapgood G, Zheng Y, Sehn LH, Villa D, Klasa R, Gerrie AS, Shenkier T, Scott DW, Gascoyne RD, Slack GW, Parsons C, Morris J, Pickles T, Connors JM, Savage KJ. Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. Journal of Clinical Oncology 2016; 34(21): 2493-500.
  18. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Santucci Silva R, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsoon C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M. Ibrutinib compared with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukemia or mall lymphocytic lymphoma (HELIOS): a randomized, double-bilnd, phase 3 study.  Lancet Oncology 2016; 17(2): 200-11.
  19. El-Galaly TC, Hutchings M, Villa D. Reply to Adams et al: “Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?” American Journal of Hematology 2016; 92(2): E2-3.
  20. Kansara R, Shenkier T, Connors J, Gerrie A, Klasa R, Savage K, Sehn L, Villa D. Rituximab with high-dose methotrexate in the management of primary central nervous system diffuse large B-cell lymphoma. American Journal of Hematology 2015; 90(12): 1149-54.
  21. El-Galaly TC, Villa D (shared first authorship), Alzahrani M, Hansen JW, Sehn LH, Wilson D, Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with DLBCL. American Journal of Hematology 2015; 90(11): 1041-1046.
  22. Brooks E, Connors JM, Sehn LH, Gascoyne RD, Savage KJ, Shenkier TN, Klasa R, Gerrie AS, Skinnider B, Slack GS, Villa D. Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with Hodgkin lymphoma. Leukemia & Lymphoma 2016; 57(4): 872-9.
  23. Oh DH, Li H, Duan Q, Villa D, Peters A, Chua N, Owen CJ, Connors JM, Stewart D. Quantifying benefit of autologous transplantation for relapsed follicular lymphoma patients via instrumental variable analysis. Biology of Blood and Marrow Transplantation 2016; 22: 941-948.
  24. Wan D, Villa D, Woods R, Yerushalmi R, Gelmon K. Breast cancer subtype variation by race and ethnicity in a diverse population in British Columbia. Clincal Breast Cancer 2016; 16(3): 49-55.
  25. Hay K, Lee B, Goktepe O, Connors JM, Sehn LH, Savage KJ, Klasa R, Shenkier T, Gerrie A, Villa D.. Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma (DLBCL). Leukemia & Lymphoma 2016: 57(2).
  26. Hitz F, Connors JM, Gascoyne RD, Hoskins P, Moccia A, Savage KJ, Sehn LH, Villa D, Klasa R. Outcome of patients with primary refractory diffuse large B-cell lymphoma after R-CHOP treatment. Ann Hematol 2015; 94(11): 1839-43.
  27. Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW. “Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation.” Clinical Lymphoma Myeloma Leukemia 2015; 15 (6); 341-348.
  28. Villa D, George A, Seymour JF, Toze CL, Crump M, Lee C, Buckstein R, Stewart DA, MacDonald D, Foley R, Xenocostas A, Sabloff M, Chua N, Couture F, Larouche JF, Cohen S, Savage KJ, Connors JM, Panzarella T, Carney DA, Dickinson M, Kuruvilla J. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed non-follicular indolent lymphoma. Biology of Blood and Marrow Transplantation 2014; 20(11): 1813-8.
  29. Xing K, Connors JM, Lai A, Al-Mansour M, Sehn LH, Villa D, Klasa R, Shenkier T, Gascoyne RD, Skinnider B, Savage K. Advanced stage nodular lymphocyte predominant Hodgkin lymphoma compared to classical Hodgkin lymphoma: a matched pair outcome analysis. Blood 2014; 123(23): 3567-73.
  30. Or C, Kirker AW, Rasmussen S, Villa D, Gerrie AS, Forooghian F, et al. Double-hit primary vitreoretinal lymphoma. Canadian Journal of Ophthalmology. 2014; 49(3): e73-6.
  31. Lee B, Goktepe O, Hay K, Connors J, Sehn L, Savage K, Shenkier T, Klasa R, Gerrie A, Villa D. Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia. The Oncologist 2014; 19(3): 283-90.
  32. Villa, D. How I treat primary central nervous system lymphoma. Canadian Perspectives in Clinical Hematology. 2014; 1(1): 4-7.
  33. Villa, D and Skinnider B. Herpes Simplex Virus Lymphadenitis. 2014; 123(1):12.
  34. Villa D, M. Crump, A. Keating, T. Panzarella, B. Feng, J. Kuruvilla. “Outcome of Patients with Transformed Indolent Non-Hodgkin’s Lymphoma Referred for Autologous Stem Cell Transplantation.” Annals of Oncology 2013; 24(6): 1603-9.
  35. Bradley KL, Tyldesley S, Speers CH, Woods R, Villa D. Contemporary Systemic Therapy for Male Breast Cancer. Clin Breast Cancer (Epub Oct 1, 2013)
  36. Panzarella T, Villa D, Kuruvilla J. Reply to C.s. Tam et Al. J Clin Oncol 2013;31(25):3167-8.
  37. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013 Jun 1;31(16):1970-6.
  38. Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, MacDonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol. 2013 Mar 20;31(9):1164-71.
  39. Davidson, I. Cromwell, S. Ellard, C. Lohrisch, K. Gelmon, T. Shenkier, D. Villa, H. Lim, S. Sun, S. Taylor, B. Czerkawski, M. Hayes, D. Ionescu, C. Yoshizawa, C. Chao, S. Peacock, S. Chia. “A Prospective Clinical Utility and Pharmacoeconomic Study of the Impact of the 21-Gene Recurrence Score® assay in Estrogen Receptor Positive Node Negative Breast Cancer.” European Journal of Cancer 2013; 49(11): 2469-75.
  40. Metcalf C, Villa D. Sugar-coating of the cerebellum. J Cancer Biol Res. 2013; 1(2): 1010
  41. Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, Fortuno ES 3rd, Xu W, Shi L, Kukreti V, Crump M, Kuruvilla J. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leuk Lymphoma. 2013 Jul;54(7):1387-95.
  42. Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf D, Peacock S. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. Eur J Cancer. 2012; 48(13): 1969-76.
  43. Villa D, Seshadri T, Puig N, Massey C, Tsang R, Keating A, Crump M, Kuruvilla J. Second Line Salvage Chemotherapy for Transplant-Eligible Patients with Hodgkin Lymphoma Resistant to Platinum-Containing First-Line Salvage Chemotherapy. Haematologica. 2012 May;97(5):751-7. Epub 2011 Dec 16.
  44. Renouf DJ, Lim HJ, Speers C, Villa D, Gill S, Blanke CD, O’Reilly SE, Kennecke H. Survival for Metastatic Colorectal Cancer in the Bevacizumab Era: A population-based Analysis. Clin Colorectal Cancer. 2011 Jun;10(2):97-101. Epub 2011 Apr 22.
  45. Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse Large B-cell Lymphoma with Renal Involvement: Outcome and Risk of Central Nervous System Relapse. Haematologica. 2011 Jul;96(7):1002-7. Epub 2011 Apr 12.
  46. Mackay H, McGee JD, Villa D, Gubbay J, Tinker LM, Shi L, Kuruvilla J, Wang L, MacAlpine K, Oza AM. Evaluation of Pandemic H1N1 (2009) Influenza Vaccine in Adults with Solid Tumor and Hematological Malignancies on Active Systemic Treatment. J Clin Virol. 2011 Mar;50(3):212-6. Epub 2010 Dec 17.
  47. Villa D, Knowling M. Acute saddle pulmonary embolism in Ewing sarcoma. J Pediatr Hematol Oncol. 2010 Jul;32(5):e210-2.
  48. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology 2010; 5(21):1046-52.
  49. Savoia E, Morano J, Cote D, Rampal S, Villa D, Testa MA. Public health preparedness evaluation and measurement. Italian Journal of Public Health 2004;1(1-2):56.